[1] YANG D,WANG Z,CHEN Y,et al.Interactions between gut microbes and NLRP3 inflammasome in the gut-brain axis[J].Comput Struct Biotechnol J,2023,21:2215-2227.
[2] STAFF N P,GRISOLD A,GRISOLD W,et al.Chemotherapy-induced peripheral neuropathy:a current review[J].Ann Neurol,2017,81(6):772-781.
[3] MONTASSIER E,GASTINNE T,VANGAY P,et al.Chemotherapy-driven dysbiosis in the intestinal microbiome[J].Aliment Pharmacol Ther,2015,42(5):515-528.
[4] PEREIRA A F,DE OLIVEIRA F F B,DE FREITAS ALVES B W,et al.Neurotoxic effect of oxaliplatin:comparison with its oxalate-free analogue Cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)](LLC-1402) in mice[J].Toxicol Appl Pharmacol,2018,340:77-84.
[5] KIM Y K,SHIN C.The microbiota-gut-brain axis in neuropsychiatric disorders:pathophysiological mechanisms and novel treatments[J].Curr Neuropharmacol,2018,16(5):559-573.
[6] 郭昌,赵文韬,胡丰良.奥沙利铂神经毒性的机制及防治研究进展[J].现代中西医结合杂志,2020,29(9):1022-1026.
[7] REEH P W,FISCHER M J M.Nobel somatosensations and pain[J].Pflugers Arch,2022,474(4):405-420.
[8] POTENZIERI A,RIVA B,RIGOLIO R,et al.Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors[J].Pain,2020,161(2):405-415.
[9] KHAKH B S,SOFRONIEW M V.Diversity of astrocyte functions and phenotypes in neural circuits[J].Nat Neurosci,2015,18(7):942-952.
[10] WATKINS L R,MILLIGAN E D,MAIER S F.Glial activation:a driving force for pathological pain[J].Trends Neurosci,2001,24(8):450-455.
[11] GARRISON C J,DOUGHERTY P M,KAJANDER K C,et al.Staining of glial fibrillary acidic protein(GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury[J].Brain Res,1991,565(1):1-7.
[12] BINSHTOK A M,WANG H,ZIMMERMANN K,et al.Nociceptors are interleukin-1beta sensors[J].J Neurosci,2008,28(52):14062-14073.
[13] WANG X M,LEHKY T J,BRELL J M,et al.Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy[J].Cytokine,2012,59(1):3-9.
[14] XU T,ZHANG X L,OU-YANG H D,et al.Epigenetic upregulation of CXCL12 expression mediates antitubulin chemotherapeutics-induced neuropathic pain[J].Pain,2017,158(4):637-648.
[15] YANG H L,LI M M,ZHOU M F,et al.Links between gut dysbiosis and neurotransmitter disturbance in chronic restraint stress-induced depressive behaviours:the role of inflammation[J].Inflammation,2021,44(6):2448-2462.
[16] ZIPP F,BITTNER S,SCHAFER D P.Cytokines as emerging regulators of central nervous system synapses[J].Immunity,2023,56(5):914-925.
[17] JAIN P,HASSAN A,HERZOG H,et al.Peptide YY and neuropeptide Y in regulation of pain and spatial learning and memory[J].BMC Pharmacol Toxicol,2012,13(suppl 1):A58.
[18] STRANDWITZ P.Neurotransmitter modulation by the gut microbiota[J].Brain Res,2018,1693(Pt B):128-133.
[19] ZHONG S,ZHOU Z,LIANG Y,et al.Targeting strategies for chemotherapy-induced peripheral neuropathy:does gut microbiota play a role?[J].Crit Rev Microbiol,2019,45(4):369-393.
[20] DELEEMANS J M,CHLEILAT F,REIMER R A,et al.The chemo-gut study:investigating the long-term effects of chemotherapy on gut microbiota,metabolic,immune,psychological and cognitive parameters in young adult cancer survivors; study protocol[J].BMC Cancer,2019,19(1):1243-1251.
[21] STRINGER A M,GIBSON R J,BOWEN J M,et al.Chemotherapy-induced modifications to gastrointestinal microflora:evidence and implications of change[J].Curr Drug Metab,2009,10(1):79-83.
[22] SOARES P M,MOTA J M,GOMES A S,et al.Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution[J].Cancer Chemother Pharmacol,2008,63(1):91-98.
[23] DANIELE B,SECONDULFO M,DE VIVO R,et al.Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer[J].J Clin Gastroenterol,2001,32(3):228-230.
[24] CUOZZO M,CASTELLI V,AVAGLIANO C,et al.Effects of chronic oral probiotic treatment in paclitaxel-induced neuropathic pain[J].Biomedicines,2021,9(4):346-352.
[25] DRUART C,BINDELS L B,SCHMALTZ R,et al.Ability of the gut microbiota to produce PUFA-derived bacterial metabolites:proof of concept in germ-free versus conventionalized mice[J].Mol Nutr Food Res,2015,59(8):1603-1613.
[26] RHEE S H,POTHOULAKIS C,MAYER E A.Principles and clinical implications of the brain-gut-enteric microbiota axis[J].Nat Rev Gastroenterol Hepatol,2009,6(5):306-314.
[27] YAMANBAEVA G,SCHAUB A C,SCHNEIDER E,et al.Effects of a probiotic add-on treatment on Fronto-limbic brain structure,function,and perfusion in depression:secondary neuroimaging findings of a randomized controlled trial[J].J Affect Disord,2023,324:529-538.
[28] 王丙开,王志,武伦,等.粪菌移植在功能性便秘治疗中的价值及存在的问题[J].现代医学,2021,49(7):827-831.
[29] YEH Y M,CHENG H T,LE P H,et al.Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory Clostridioides difficile infection and report of preliminary outcome[J].Biomed J,2021,45(3):504-511.
[30] GRIZOTTE-LAKE M,ZHONG G,DUNCAN K,et al.Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate Interleukin-22 activity and prevent microbial dysbiosis[J].Immunity,2018,49(6):1103-1115.
[31] ZHAO Z,NING J,BAO X Q,et al.Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis[J].Microbiome,2021,9(1):226-231.
[32] SUN M F,ZHU Y L,ZHOU Z L,et al.Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice:gut microbiota,glial reaction and TLR4/TNF-α signaling pathway[J].Brain Behav Immun,2018,70:48-60.
[33] KEIIY B J,TEBAS P.Clinical practice and infrastructure review of fecal microbiota transplantation for clostridium difficile infection[J].Chest,2017,153(1):266-277.
[34] AZIMIRAD M,YADEGAR A,ASADZADEH AGHDAEI H,et al.Enterotoxigenic Clostridium perfringens infection as an adverse event after faecal microbiota transplantation in two patients with ulcerative colitis and recurrent Clostridium difficile infection:a neglected agent in donor screening[J].J Crohns Colitis,2019,13(7):960-961.
[35] 娄彦妮,田爱平,张侠,等.中医外治化疗性周围神经病变的多中心、随机、双盲、对照临床研究[J].中华中医药杂志,2014,29(8):2682-2685.
[36] 付志文,屈留新.黄芪桂枝五物汤治疗神经根型颈椎病的Meta分析[J].现代医学,2022,50(4):434-440.
[37] 朱飞波,洪用伟,符明明,等.补阳还五汤加减治疗硼替佐米相关周围神经病变的临床观察[J].现代实用医学,2018,30(10):1308-1309.
[38] 苏妙芳.基于数据挖掘与网络药理学方法的黄芪桂枝五物汤方证研究[D].哈尔滨:黑龙江中医药大学,2023.
[39] ZHANG Z,YE J,LIU X,et al.Huangqi Guizhi Wuwu decoction alleviates oxaliplatin-induced peripheral neuropathy via the gut-peripheral nerve axis[J].Chin Med,2023,18(1):114-121.
[40] PEI L X,YI Y,GUO J,et al.The effectiveness and safety of acupuncture/electroacupuncture for chemotherapy-induced peripheral neuropathy:a systematic review and meta-analysis[J].Acupunct Med,2022,41(2):73-85.
[41] 崔光卫,程怀锦,陈颢,等.电针对大鼠奥沙利铂所致周围神经毒性的缓解作用[J].中华中医药杂志,2017,32(6):2670-2672.
[42] 曾晓铃,徐世芬,殷萱.针刺治疗化疗后周围神经病变研究进展[J].中国中医药信息杂志,2024,31(5):190-196.
[43] 陈淼,张庆乾,余志红,等.化疗所致周围神经病变外治法概述[J].中华中医药杂志,2019,34(10):4750-4753.
[44] 朱平,王传思,杨惠.全息刮痧疗法对胃癌术后患者早期肠内营养耐受性的影响[J].护理学杂志,2022,37(2):35-37.
[45] 王鳕,唐建清,赵晔.李氏铜砭刮痧在奥沙利铂所致周围神经病变中的运用[J].中医药导报,2021,27(12):188-190.
[46] 林碧容,鲜玉军,晋静,等.辨证循经刮痧对颈椎病患者的中医临床护理研究[J].现代医学,2020,48(2):260-263. |
